SAN DIEGO--(BUSINESS WIRE)--PURE Bioscience, Inc. (NASDAQ: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today reported product revenues for the fiscal third quarter ended April 30, 2011 of $128,400, compared with product revenues of $563,500 for the same quarter of the prior fiscal year. The Company reported a net loss of $1,817,800 or $(0.05) per share for the fiscal 2011 third quarter, compared with a net loss of $1,610,000 or $(0.05) per share for the fiscal 2010 third quarter.
